Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Colletti

Showing results (71-80 of 75) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 75 results.
Bioorganic & Medicinal Chemistry Letters|June 26, 2007
Agonist lead identification for the high affinity niacin receptor GPR109aTawfik Gharbaoui, Philip J Skinner, Young-Jun Shin, et al.
Journal of Medicinal Chemistry|March 23, 2012
(1aR,5aR)1a,3,5,5a-Tetrahydro-1H-2,3-diaza-cyclopropa[a]pentalene-4-carboxylic acid (MK-1903): a potent GPR109a agonist that lowers free fatty acids in humansP Douglas Boatman, Brett Lauring, Thomas O Schrader, et al.
Science Translational Medicine|August 24, 2012
Niacin lipid efficacy is independent of both the niacin receptor GPR109A and free fatty acid suppressionBrett Lauring, Andrew K P Taggart, James R Tata, et al.
Nature Structural & Molecular Biology|June 6, 2017
Structural basis for the cooperative allosteric activation of the free fatty acid receptor GPR40Jun Lu, Noel Byrne, John Wang, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|March 25, 2014
Development of a liver-targeted siRNA delivery platform with a broad therapeutic window utilizing biodegradable polypeptide-based polymer conjugatesStephanie E Barrett, Rob S Burke, Marc T Abrams, et al.
Pageof 8

Showing results (71-80 of 75) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 75 results.
Bioorganic & Medicinal Chemistry Letters|June 26, 2007
Agonist lead identification for the high affinity niacin receptor GPR109aTawfik Gharbaoui, Philip J Skinner, Young-Jun Shin, et al.
Journal of Medicinal Chemistry|March 23, 2012
(1aR,5aR)1a,3,5,5a-Tetrahydro-1H-2,3-diaza-cyclopropa[a]pentalene-4-carboxylic acid (MK-1903): a potent GPR109a agonist that lowers free fatty acids in humansP Douglas Boatman, Brett Lauring, Thomas O Schrader, et al.
Science Translational Medicine|August 24, 2012
Niacin lipid efficacy is independent of both the niacin receptor GPR109A and free fatty acid suppressionBrett Lauring, Andrew K P Taggart, James R Tata, et al.
Nature Structural & Molecular Biology|June 6, 2017
Structural basis for the cooperative allosteric activation of the free fatty acid receptor GPR40Jun Lu, Noel Byrne, John Wang, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|March 25, 2014
Development of a liver-targeted siRNA delivery platform with a broad therapeutic window utilizing biodegradable polypeptide-based polymer conjugatesStephanie E Barrett, Rob S Burke, Marc T Abrams, et al.
Pageof 8